Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Corrado Ficorella, Simone Scagnoli et al.|European Journal of Cancer|2020Cited by 71
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective studyÉlisa Gobbini, Silvia Novello, Domenico Galetta et al.|Lung Cancer|2017Cited by 36
Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatmentMarzia Del Re, Romano Danesi, Paola Bordi et al.|Oncotarget|2017Cited by 12
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre studyOlga Nigro, Corrado Ficorella, Graziella Pinotti et al.|medRxiv|2020Cited by 6
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective studyÉlisa Gobbini, Silvia Novello, Rita Chiari et al.|Clinical & Translational Oncology|2019Cited by 5